Lilly unveils early long-term data on eczema drug that could chip away at Dupixent market
As it looks to bring lebrikizumab to market, Eli Lilly shared initial one-year data for 10 patients on its atopic dermatitis drug.
Of the 10 patients who responded to lebrikizumab at 16 weeks, 8 maintained skin clearance at one year on the two-week or four-week regimen, Lilly reported in a press release. Previously, Lilly disclosed 16-week Phase III data that showed just over 40% of patients on lebrikizumab got almost clear skin or better compared to just over 20% in the control group.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
